Lucent Diagnostics, a division of Quanterix Corporation, has formed a partnership with Life Line Screening (LLS) to provide innovative blood-based diagnostics across the United States. This collaboration aims to enhance community health by offering non-invasive biomarker tests that identify chronic conditions, starting with initiatives already underway in Florida, California, and Texas.
The partnership addresses a critical public health need, particularly as an estimated 7 million Americans currently live with Alzheimer’s disease, with an additional 6-7 million experiencing symptoms of Mild Cognitive Impairment (MCI), according to the Alzheimer’s Association. The availability of scalable testing options is essential for early detection and treatment of these conditions.
“Too many chronic conditions go undetected until they become life-altering events,” stated Jim Waters, Chief Operating Officer at Life Line Screening. He emphasized that this collaboration will help fulfill their mission of uncovering asymptomatic risks more equitably. Waters expressed optimism about the potential impact of this partnership on countless lives, facilitating more informed treatment pathways.
The implementation of these blood tests will be facilitated through LLS’s mobile delivery model, which provides testing opportunities in accessible venues such as community centers, churches, and senior centers. The results will be shared with primary care physicians, supporting early intervention and proactive lifestyle management for adults.
“Scientific rigor shouldn’t stop at the laboratory door,” remarked Zachary Fernandes, General Manager for Lucent Diagnostics. He underscored the importance of integrating validated scientific methods into community testing networks, ensuring widespread access to critical health information. This initiative is seen as a pivotal step toward the earlier and more reliable detection of Alzheimer’s disease.
Life Line Screening operates nationally, reaching individuals in both urban and underserved rural areas. As a leading provider of community-based preventive health screenings, LLS hosts over 15,000 events annually, empowering over 11 million people to understand their health risks and take proactive measures.
The collaboration between Lucent Diagnostics and Life Line Screening marks a significant advancement in the field of community health. By utilizing cutting-edge technology and a comprehensive reach, the partnership aims to improve the early detection of chronic conditions, ultimately enhancing the quality of care for individuals nationwide.
For more information about Life Line Screening, visit www.lifelinescreening.com. To learn more about Lucent Diagnostics and Quanterix, go to www.lucentdiagnostics.com.
